Clinical trial
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
NCT04169932 is registered in ClinicalTrials.gov with Shanghai Longyao Biotechnology Inc., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
- Lead sponsor
- Shanghai Longyao Biotechnology Inc., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 22, 2019
- Completion date
- November 22, 2022
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin lymphoma, relapsed and refractory b cell lymphoma